Relief Therapeutics Holding has a quick ratio of 3.80. It generally indicates good short-term financial strength.
The historical rank and industry rank for Relief Therapeutics Holding's Quick Ratio or its related term are showing as below:
XSWX:RLF'
s Quick Ratio Range Over the Past 10 Years
Min: 0.08 Med: 1.16 Max: 7
Current: 3.8
During the past 13 years, Relief Therapeutics Holding's highest Quick Ratio was 7.00. The lowest was 0.08. And the median was 1.16.
XSWX:RLF's Quick Ratio is not ranked
in the Biotechnology industry.
Industry Median: 3.6
vs XSWX:RLF: 3.80
Relief Therapeutics Holding (XSWX:RLF) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Relief Therapeutics Holding Quick Ratio Related Terms
Relief Therapeutics Holding Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:RLF vs KTTA, OSRH, LIMN: Quick Ratio Comparison
For the Biotechnology subindustry, Relief Therapeutics Holding's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Relief Therapeutics Holding Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Relief Therapeutics Holding's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Relief Therapeutics Holding's Quick Ratio falls into.
Relief Therapeutics Holding Quick Ratio Calculation
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Relief Therapeutics Holding (XSWX:RLF) has a Quick Ratio of 3.80 as of Jun. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Relief Therapeutics Holding and its competitors. This is 228% above median its historical median of 1.16. Over the past decade, Relief Therapeutics Holding's Quick Ratio has ranged from 0.08 to 7.00.
Is Relief Therapeutics Holding's Quick Ratio too high?
Relief Therapeutics Holding's current Quick Ratio of 3.80 is 228% above median its 10-year median of 1.16. Over the past 10 years, this metric has ranged from a low of 0.08 to a high of 7.00. The Biotechnology industry median Quick Ratio is 3.60. Relief Therapeutics Holding's value of 3.80 is 5.6% above this industry median. Overall, Relief Therapeutics Holding has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Relief Therapeutics Holding's Quick Ratio compare to KTTA and OSRH?
Relief Therapeutics Holding's Quick Ratio of 3.80 can be compared against companies in the Biotechnology industry. The industry median Quick Ratio is 3.60. Relief Therapeutics Holding's value of 3.80 is 5.6% above this benchmark. Historically, Relief Therapeutics Holding's own Quick Ratio has ranged from 0.08 to 7.00 over the past decade. While the company's 10-year median is 1.16 vs. the industry median of 3.60, Relief Therapeutics Holding has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Relief Therapeutics Holding's current Quick Ratio of 3.80 is 5.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Relief Therapeutics Holding and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Relief Therapeutics Holding's current Quick Ratio is 3.80, which is 228% above median its own 10-year median of 1.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Relief Therapeutics Holding stock overvalued right now?
Relief Therapeutics Holding (XSWX:RLF) has a current Quick Ratio of 3.80. The stock's GF Value™ is CHF6.28, compared to a current price of CHF3.00 — trading 52.2% below its estimated fair value. The current Quick Ratio is 3.80, which is 228% above median its 10-year median of 1.16 and 5.6% above the Biotechnology industry median of 3.60. Relief Therapeutics Holding's overall GF Score™ is 20/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Relief Therapeutics Holding (XSWX:RLF), the current Quick Ratio is 3.80 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Relief Therapeutics Holding (XSWX:RLF) Overvalued in 2026?
Based on GuruFocus' analysis, Relief Therapeutics Holding stock appears to be undervalued.
The current stock price of CHF3.00 is trading 52.2% below its estimated GF Value™ of CHF6.28.
Key valuation signals for XSWX:RLF:
Quick Ratio: 3.80 (228% above median its 10-year median of 1.16)
GF Value™: CHF6.28 vs. price of CHF3.00 (52.2% below fair value)
Industry Position: 5.6% above the Biotechnology median
No single metric tells the full story. See the XSWX:RLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products. It mainly develops drugs of natural human origin. It has a focus on commercial products, and the development program pipeline is focused on three main areas: rare genetic, metabolic disorders, rare connective tissue disorders, and rare lung diseases. Its pipeline includes various drug candidates in their different stages of development, such as RLF-TD011 and RLF-100, among others. It also has commercial legacy products like Cambia, Setofilm, Voltadol, and Voltfast, among others. Geographically, the company generates a majority of its revenue from Europe (excluding Switzerland) and the rest from North America, Switzerland, and the rest of the world.
20GF Score
Get the complete analysis for XSWX:RLF
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:RLF has been successfully added to your 
